Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report released on Monday.

Pulse Biosciences Stock Performance

PLSE opened at $16.73 on Monday. The business has a 50 day moving average price of $18.67 and a 200 day moving average price of $18.13. Pulse Biosciences has a twelve month low of $6.60 and a twelve month high of $25.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pulse Biosciences by 14.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company’s stock valued at $667,000 after purchasing an additional 4,773 shares during the last quarter. Panoramic Capital LLC acquired a new stake in Pulse Biosciences in the 4th quarter valued at approximately $846,000. Deutsche Bank AG grew its holdings in Pulse Biosciences by 65.1% in the 4th quarter. Deutsche Bank AG now owns 16,795 shares of the company’s stock valued at $292,000 after buying an additional 6,625 shares during the last quarter. Bank of America Corp DE increased its position in Pulse Biosciences by 0.4% in the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company’s stock worth $13,727,000 after buying an additional 2,884 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Pulse Biosciences by 98.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock worth $29,000 after buying an additional 838 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.